BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24147068)

  • 21. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma.
    Capasso M; Lasorsa VA; Cimmino F; Avitabile M; Cantalupo S; Montella A; De Angelis B; Morini M; de Torres C; Castellano A; Locatelli F; Iolascon A
    Cancer Res; 2020 Feb; 80(3):382-393. PubMed ID: 31784426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in PIK3CA are infrequent in neuroblastoma.
    Dam V; Morgan BT; Mazanek P; Hogarty MD
    BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of endothelial cell migration by constitutively active LPA(1)-expressing tumor cells.
    Kitayoshi M; Kato K; Tanabe E; Yoshikawa K; Fukui R; Fukushima N; Tsujiuchi T
    Biochem Biophys Res Commun; 2012 Jun; 422(2):339-43. PubMed ID: 22580000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Constitutively active lysophosphatidic acid receptor-1 enhances the induction of matrix metalloproteinase-2.
    Kato K; Fukui R; Okabe K; Tanabe E; Kitayoshi M; Fukushima N; Tsujiuchi T
    Biochem Biophys Res Commun; 2012 Jan; 417(2):790-3. PubMed ID: 22197817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.
    Lee PJ; Yoo NS; Hagemann IS; Pfeifer JD; Cottrell CE; Abel HJ; Duncavage EJ
    Exp Mol Pathol; 2017 Feb; 102(1):156-161. PubMed ID: 28093192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
    Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
    PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NONO enhances mRNA processing of super-enhancer-associated GATA2 and HAND2 genes in neuroblastoma.
    Zhang S; Cooper JA; Chong YS; Naveed A; Mayoh C; Jayatilleke N; Liu T; Amos S; Kobelke S; Marshall AC; Meers O; Choi YS; Bond CS; Fox AH
    EMBO Rep; 2023 Feb; 24(2):e54977. PubMed ID: 36416237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
    George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
    Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma.
    Kong XT; Choi SH; Inoue A; Xu F; Chen T; Takita J; Yokota J; Bessho F; Yanagisawa M; Hanada R; Yamamoto K; Hayashi Y
    Cancer Res; 1997 Sep; 57(17):3772-8. PubMed ID: 9288786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.